MedPath

Does postoperative treatment with parathyroidea hormone Forteo®improve the disability inelderly patients undergoing spinal stabilization fusion surgery comparedwith patients treated with placebo. If that is the case, is there a correlationbetween improvement of disability and solid osseous healing?

Phase 1
Conditions
Spinal stenosis
MedDRA version: 14.1Level: LLTClassification code 10041597Term: Spinal stenosis of lumbar regionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Registration Number
EUCTR2011-006152-36-DK
Lead Sponsor
Middelfart Rygsektor
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Spinal stenosis verified by MRI
Age 60 or above
No diagnosed dementia
(MMSE 24 of 30 correct answers)
Considerable reduction in walking distance which
has not improved during conservative treatment

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 85

Exclusion Criteria

Contraindication for PTH treatment
Major deformity
Mental illness
Spinal cord compression due to infection or
malignant disease
Resent spinal fracture
hypercalcemia
Reduced kidney function
Metabolic bone disease, including
hypophosphatemia
Untreated anti coagulant treatment
Previous radiation therapy
Haematological disorders
Previously fusion spinal surgery
Age under 60

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath